Current and potential chemotherapeutic agents used for induction chemotherapy in the treatment of breast cancer.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Current pharmaceutical design

• Publication date

  2000-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1381612003401073PMID 10637382
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen

  2005cited by this paper
• Arimidex®: A potent and selective fourth-generation aromatase inhibitor

  2004cited by this paper
• Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy

  2004cited by this paper
• Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial

  2004cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Role of aromatase inhibitors in advanced breast cancer.

  1999cited by this paper
• Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.

  1999cited by this paper
• Molecular biology of the estrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene.

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Late effects of treatment for early-stage Hodgkin's disease.

  1998cited by this paper
• erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

  1998cited by this paper
• Letrozole. A review of its use in postmenopausal women with advanced breast cancer.

  1998cited by this paper
• Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

  1998cited by this paper
• Pivotal trials of letrozole: a new aromatase inhibitor.

  1998cited by this paper
• Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

  1998cited by this paper
• Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.

  1998cited by this paper
• Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.

  1998cited by this paper
• Second cancers following pediatric Hodgkin's disease.

  1998cited by this paper
• Aromatase inhibitors and their use in the adjuvant setting.

  1998cited by this paper
• Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow.

  1998cited by this paper
• HER‐2/neu Signal Transduction in Human Breast and Ovarian Cancer

  1997cited by this paper
• Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.

  1997cited by this paper
• Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer

  1997cited by this paper
• Toremifene

  1997cited by this paper
• Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.

  1997cited by this paper
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

  1997cited by this paper
• Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

  1997cited by this paper
• Use of aromatase inhibitors in postmenopausal women with advanced breast cancer

  1997cited by this paper
• The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

  1997cited by this paper
• Regulation of aromatase activity within the breast.

  1997cited by this paper
• A Risk-Benefit Assessment of Anthracycline Antibiotics in Antineoplastic Therapy

  1996cited by this paper
• Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

  1996cited by this paper
• Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen.

  1996cited by this paper
• c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

  1996cited by this paper
• Primary chemotherapy for early breast cancer.

  1996cited by this paper
• Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog?

  1996cited by this paper
• What is the role of thymidine phosphorylase in tumor angiogenesis.

  1996cited by this paper
• Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

  1996cited by this paper
• Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.

  1996cited by this paper
• A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women

  1996cited by this paper
• An overview of phase II studies of docetaxel in patients with metastatic breast cancer.

  1995cited by this paper
• Endometrial carcinoma and tamoxifen: clearing up a controversy.

  1995cited by this paper
• Primary chemotherapy in surgically resectable breast cancer

  1995cited by this paper
• Early clinical studies with docetaxel. Docetaxel Investigators Group.

  1995cited by this paper
• Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.

  1995cited by this paper
• Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells

  1995cited by this paper
• Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.

  1995cited by this paper
• Preclinical evaluation of docetaxel (Taxotere).

  1995cited by this paper
• Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

  1995cited by this paper
• Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.

  1995cited by this paper
• Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment.

  1994cited by this paper
• Anthracyclines: cardiotoxicity and its prevention.

  1994cited by this paper
• Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen

  1994cited by this paper
• Continuous 5-fluorouracil in the treatment of breast cancer.

  1994cited by this paper
• Paclitaxel (Taxol) in breast cancer.

  1994cited by this paper
• c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

  1994cited by this paper
• Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines.

  1994cited by this paper
• Dose optimization of anthracyclines.

  1994cited by this paper
• Clinical Pharmacokinetics of Epirubicin

  1994cited by this paper
• Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene.

  1993cited by this paper
• Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.

  1993cited by this paper
• Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.

  1993cited by this paper
• Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer.

  1993cited by this paper
• Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs

  1993cited by this paper
• Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition.

  1993cited by this paper
• Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.

  1993cited by this paper
• Inhibition of angiogenesis by antiestrogens.

  1993cited by this paper
• Tamoxifen as adjuvant therapy in breast cancer. Current status.

  1993cited by this paper
• Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging.

  1992cited by this paper
• Taxol: the first of the taxanes, an important new class of antitumor agents.

  1992cited by this paper
• The management of locally advanced breast cancer.

  1992cited by this paper
• 4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer.

  1992cited by this paper
• Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression.

  1992cited by this paper
• Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.

  1992cited by this paper
• Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment.

  1992cited by this paper
• Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes.

  1992cited by this paper
• Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.

  1992cited by this paper
• Long term effects of tamoxifen on blood lipid values in breast cancer.

  1992cited by this paper
• The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue.

  1991cited by this paper
• Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin.

  1991cited by this paper
• Biologically active taxol analogues with deleted A-ring side chain substituents and variable C-2' configurations.

  1991cited by this paper
• Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.

  1991cited by this paper
• A potent specific pure antiestrogen with clinical potential.

  1991cited by this paper
• Relationships between the structure of taxol analogues and their antimitotic activity.

  1991cited by this paper
• Clinical Pharmacokinetics of Cyclophosphamide

  1991cited by this paper
• Impact of radiation therapy and/or chemotherapy on the risk for a second malignancy after breast cancer

  1990cited by this paper
• A new insight into adriamycin-induced cardiotoxicity.

  1990cited by this paper
• Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity.

  1990cited by this paper
• Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice.

  1990cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Topoisomerase-targeting antitumor drugs.

  1989cited by this paper
• Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases

  1989cited by this paper
• The human estrogen receptor has two independent nonacidic transcriptional activation functions.

  1989cited by this paper
• Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

  1989cited by this paper
• Topoisomerases in human disease.

  1988cited by this paper
• The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer.

  1988cited by this paper
• Novel antioestrogens without partial agonist activity.

  1988cited by this paper
• Fluorouracil: biochemistry and pharmacology.

  1988cited by this paper

• Investigation of the anti-breast cancer efficacy and mechanisms of disulfiram

  2015cites this paper
• Novel 4-azasteroidal N-glycoside analogues bearing sugar-like D ring: synthesis and anticancer activities.

  2011cites this paper
• Design, synthesis, and anticancer activities of novel perfluoroalkyltriazole-appended 2'-deoxyuridines.

  2010cites this paper
• Potentiation of drug-induced cytotoxicity by conjugated linoleic acids (CLA) in in vitro models of drug-resistant cancer

  2009influential citation
• Chemotherapy dosing part I: scientific basis for current practice and use of body surface area.

  2007cites this paper
• Anticancer alpha-helical peptides and structure/function relationships underpinning their interactions with tumour cell membranes.

  2006cites this paper
• Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus.

  2006cites this paper
• Glutathion S transferase pi indicates chemotherapy resistance in breast cancer.

  2003cites this paper
• SERMs: evolutionary chemistry, revolutionary biology.

  2002cites this paper
• Does Leucovorin Alter the Intratumoral Pharmacokinetics of 5-Fluorouracil (5-FU)? A Southwest Oncology Group Study

  2002cites this paper
• Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy

  2002cites this paper
• Tumour cytochrome P450 and drug activation.

  2002cites this paper
• Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours.

  2002cites this paper
• Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial.

  2002cites this paper
• Liposomal doxorubicin (Myocet™) and conventional anthracyclines: a comparison

  2001cites this paper
• Improving the therapeutic index when using Myocet™ in the treatment of metastatic breast cancer

  2001cites this paper